Annual Report and Accounts

The report describes the company's return to profit in 2021, with revenue of €65.1 million and operating profit of €11.1 million. It highlights FDA and Canadian approvals for GI Genius, the U.S. launch of Winlevi by Sun Pharma, and the acquisition of Cassiopea, which raised Cosmo's stake to 97.57%. The report also sets out commitments to environmental responsibility, employee dignity, ethical conduct, and safe operations.